Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Vasculitis
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Vynpenta (previously AvacopanChemoCentryx)
Induction of response in adult patients with granulomatosis with polyangiitis (Wegener’s) (GPA) or microscopic polyangiitis (MPA)
Tavneos
Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).